Melanie Cole, MS (Host): Welcome to the podcast series from the
specialists at Penn Medicine.
I'm Melanie Colon.
Today we're highlighting biomarker testing in N-S-C-L-C
or non-small cell lung cancer.
Joining me is Dr.
Molina Mar Morales.
She's the medical director of the Penn Medicine Mesothelioma Program.
Dr.
Mar Morales, thank you so much for joining us today.
You recently participated in a relatively large retrospective study that found
that approximately 30% of patient's with biomarker positive disease who
underwent next generation sequencing did not receive biomarker driven targeted
therapies as their first-line treatment.
Can you tell us just a little bit about that and where biomarker
comes into play in this picture?
Melina Marmarelis, MD: Yeah, no problem.
So, we're talking about metastatic non-small cell lung cancer, so one of
the most common forms of lung cancer.
And in the.
And in the last decade we've really had an explosion in both the detection of targets
And the development of targeted therapies.
So it's become critical prior to starting any sort of therapy that we actually know
a lot of characteristics about the tumor.
So, this specifically is doing next generation sequencing on the
patient's tumor prior to receiving any sort of systemic therapy.
And what we've seen over the years is that initially when this came, to
light, we were seeing really poor rates of biomarker testing, especially
prior to initiation of therapy.
initially, over half of patient's weren't getting this recommended testing.
and now we're seeing closer to, 20 to 30% that don't get it depending
on, parts of the country and different demographics of patient's.
But it's really important both to.
Choose the correct treatment, but also to avoid treatments that might
not be effective in patient's.
So it's really precision medicine as it at its best.
Melanie Cole, MS (Host): Certainly the way that we're going in the future.
In your field now, how important is biomarker testing in N-S-C-L-C
and why is there an unmet need?
For this advantage in some patient's with biomarker, positive, advanced,
or as you said, metastatic N-S-C-L-C.
Melina Marmarelis, MD: So we know that if a target is detected, so for instance,
if a patient has a mutation in EGFR or a fusion in the ALK gene, it's really
important that they receive targeted therapy And that they not receive.
Standard chemotherapy or immunotherapy.
so for instance, immunotherapy by itself really isn't effective for patient's
that have EGFR or ALK alterations.
so it's become critical to really understand the characteristics of
the tumor before we start treatment.
Melanie Cole, MS (Host): What role has Penn Medicine played in
the discovery or advancement of biomarker testing for N-S-C-L-C?
'cause that's really exciting stuff.
Melina Marmarelis, MD: Yeah, so the gold standard is still, tissue testing.
So a patient gets a biopsy, And the biopsy undergoes next generation's.
Sequencing.
but that sometimes is not successful.
So either there's not enough tissue, or, there are issues with the amount
that's available, because there are other competing tests that we do.
So I think, the role that Penn has been able to play is really pushing
liquid biopsy to the forefront.
So, liquid biopsy is actually just a plasma-based test, meaning a blood test.
and it looks for pieces of cell-free DNA in the blood.
So little pieces of, the tumor's, DNA, that were shed into the blood.
so for the patient, the experience is quite different from a biopsy, right?
It's just a blood test They're able to get some of the same information
that you would get from next generation sequencing on tissue.
Penn has been able to play a role in a few ways.
One, is that we showed that concurrent testing, so, both liquid
and tissue testing can improve your rates of detection of a target.
So.
That makes sense, right?
Two shots on goal.
You have two ways of trying to detect a target.
You can increase your chances by, you know, more than 30%,
in detecting one of these.
And since we know that detecting and delivering a targeted
therapy has a survival advantage, that's really important.
the second piece is That is more operational.
So we have run a clinical trial across the health system, trying to
implement concurrent testing with both the liquid biopsy And the tissue.
So, this was actually something that, some of the providers may have seen
in their electronic medical record.
it popped up at the time of new patient visits and prompted
people to order the liquid biopsy testing to ensure that patient's.
Got timely testing, And the most information that we could get
prior to initiating treatment.
Melanie Cole, MS (Host): I will agree.
Liquid biopsy is.
A very exciting development and your field is really moving
very quickly right now.
Can you discuss briefly the current place of immunotherapy in lung cancer therapy
And what the future holds in that regard?
Melina Marmarelis, MD: I mean, immunotherapy is one of the most exciting
things to have come, to lung cancer.
it's one of the things that gives really durable benefit to patient's,
if they have a nice response, it's a key tool that we have.
The key to using immunotherapy is using it in the right patient's.
patient's for instance, with things like EGFR and ALK alterations don't
benefit as much from immunotherapy, but other's, that don't have these
alterations may, benefit quite a bit.
So we're using immunotherapy in a lot of different settings.
we're using it as first-line treatment for metastatic disease.
Using it, perioperatively before and after surgery potentially.
So, it really has a lot of different, roles.
And the question we're asking ourselves when we see a patient is
usually, is there a reason I shouldn't give this patient immunotherapy?
Because the default is that we're going to start with some
immunotherapy based regimen.
Melanie Cole, MS (Host): Well then along those lines, how is it
changing the need for biomarker testing in early stage N-S-C-L-C?
Tell us how they're working together.
Melina Marmarelis, MD: Yeah, I think This is the next
frontier for biomarker testing.
and it's a much more difficult problem to solve.
so in the metastatic setting, we had, cell-free DNA, which you can
pick up little pieces of the DNA in the blood, And that makes getting.
testing back, to the provider much faster.
In early stage lung cancer, you often don't have shedding into the blood.
So those tests that we were using in the metastatic setting aren't able to
detect anything in the blood, so you're really reliant on tissue testing.
thankfully there have been a number of advances, And we are able to use higher
sensitivity, cell-free DNA assays to detect some of these things in the blood.
They're.
A variety of types of tests that do this.
The ones that are being used right now that have the widest range are
tumor informed, which means that they use a piece of the patient's tumor
And then they go looking in the blood for similar things in the blood.
and because it's so specific to the patient, they can actually detect
things, with a much higher sensitivity.
So we're starting to look at that in early stage.
I don't think it's yet replacing tissue testing.
One of the challenges for tissue testing in early stages that the
tissue tests often take several weeks.
they take, two to three weeks if you're sending out often or
if you're doing a bigger panel.
And patient's don't wanna wait that long to make a decision about whether
they're gonna start some sort of chemo immunotherapy or go straight to surgery.
So one of the things we've been able to do at Penn is we have
implemented a faster, more limited.
Assay that has a turnaround time of about five days, that can get us the information
that we need actually to make that initial decision about perioperative therapy.
Melanie Cole, MS (Host): Wow, that's fascinating.
So along those lines then, how can patient's.
Patient's, you said sometimes, you know, they don't wanna wait to find out about
these therapies that are available.
How can they advocate for themselves to get complete biomarker testing so
they can move on to the therapies that work best for their specific cancer?
Melina Marmarelis, MD: Yeah, I think that's a great point.
And it's such an overwhelming time for patient's that it's hard to,
put more on them while they're navigating this new diagnosis.
But I think one thing, That I would hope for patient's is that as they're
doing their research about their new diagnosis, that they, hopefully they
come across something about biomarker testing, and I think ideally they would
talk to, their providers about it.
So, You know, that might be a surgeon or a pulmonologist The person doing
the biopsy, because often by the time they get to a medical-oncologist,
It's been several weeks, And so if we order the testing at that point, then
we're a little bit behind the ball.
Of course we're looking at additional ways to prompt the system to
actually get that testing done.
But I think, of all the questions that patient's ask, I think This is a great one
to be asking their providers as well as, has my tissue been tested, for biomarkers?
Has it gone through, sequencing?
Melanie Cole, MS (Host): That's great information.
Really important for other providers to hear as they're
counseling their patient's as well.
And as you said, it's a very confusing.
Frightening time.
So this isn't always something that comes top of mind, but
thank you for pointing that out.
I understand that a lung cancer translational center of excellence
is being developed within the thoracic oncology precision program.
What's the mission of the lung?
Cancer?
TCE Tele US Just a little bit about that.
Melina Marmarelis, MD: the translational Centers for Excellence
have existed now for some time.
And the thoracic TCE has also existed for some time.
Its initial focus was on immunotherapy.
So, this was at the.
Start about 10 years ago when immunotherapy was really new in the
lung cancer field, and it, produced some really amazing projects in that realm.
recently it's been reimagined, to focus in a little bit on some of the
biomarkers, uh, biomarker discovery That is so exciting in lung cancer right now.
We have a lot of projects that center around liquid biopsy, mostly in the
early stage setting, but some in the metastatic setting as well, and trying
to figure out how do we use these new tools that we have in order to, give
patient's better outcomes and make better treatment decisions for them.
Melanie Cole, MS (Host): Wow.
Very exciting time in your field.
As we wrap up, Dr.
Marlis biomarker testing in N-S-C-L-C, do you have any final thoughts for
other providers about this and really the importance of discussing it
with their patient's or referring to the specialists at Penn Medicine?
Melina Marmarelis, MD: I think just thinking about, the systems that we have
and how we can capture all patient's in order to make sure that all patient's
are have biomarker testing right now.
I think a lot of the time we see a patient and if we think
about it then it gets ordered.
But, having some additional, things in the background to
make sure that we're actually.
Capturing all of the information on all patient's in a timely way.
Melanie Cole, MS (Host): Thank you so much, Dr.
Mar Morales for joining us today.
A and sharing all of this exciting information.
To refer your patient to Dr.
Marlis at Penn Medicine, please call our twenty four seven provider
only line at 8 7 7 9 3 7 Penn, or you can submit your referral via
our secure online referral form by visiting our website@pennmedicine.org
slash refer your patient.
That concludes this episode from the Specialists at Penn Medicine.
I'm Melanie Cole.